Evidence map›Paper›PMID 36795364›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Assessment of Immunologically Potent Carbohydrates.

Denong Wang

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Denong WangTumor Glycomics Laboratory, SRI International Biosciences Division, Menlo Park, CA, USA. denong.wang@sri.com.

Funding

Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomasR21CA254048 · NCI · SRI INTERNATIONAL · PI WANG, DENONG · 2021 to 2022
$576k
ADAR1-Mediated HIV RNA ModificationsR21DA046144 · NIDA · SRI INTERNATIONAL · PI WANG, DENONG · 2018 to 2019
$561k
NCI NIH HHS R21 CA254048NIDA NIH HHS R21 DA046144
6 · The paper itself

Abstract

Carbohydrates have a great potential in generating structural and immunological diversities. Microbial pathogens often decorate their outmost surfaces with specific carbohydrate signatures. Carbohydrate antigens also differ significantly from protein antigens in physiochemical properties, especially in surface display of antigenic determinants in aqueous solutions. Technical optimization or modifications are often needed when we apply standard procedures for protein-based enzyme-linked immunosorbent assay (ELISA) to assess immunologically potent carbohydrates. We present here our laboratory protocols for performing carbohydrate ELISA and discuss several assay platforms that may be applied complementarily to explore the carbohydrate moieties that are critical for host immune recognition and induction of glycan-specific antibody responses.

Indexed as

CarbohydratesPolysaccharidesAntibodiesAntigensEnzyme-Linked Immunosorbent AssayProteinsAntibodiesAntigensCarbohydratesPolysaccharidesProteinsAntiglycan antibodiesCarbohydrate antigensCarbohydrate ELISAGlyco-conjugatesGlycolipidsGlycoproteinsPolysaccharides

Identifiers

PMID36795364
PMCPMC11068000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.